HC Wainwright Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $47.00

Roivant Sciences (NASDAQ:ROIV) had its price objective upped by stock analysts at HC Wainwright from $41.00 to $47.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 10.64% from the company’s current price.

Several other analysts also recently issued reports on ROIV. Weiss Ratings reissued a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Tuesday, August 25th. Jefferies Financial Group raised their price objective on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Finally, Guggenheim boosted their target price on shares of Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.68.

Roivant Sciences Stock Up 21.6%

NASDAQ:ROIV traded up $7.55 on Tuesday, hitting $42.48. The stock had a trading volume of 15,408,797 shares, compared to its average volume of 6,190,787. The business’s fifty day moving average is $35.30 and its 200 day moving average is $31.26. The company has a market cap of $30.68 billion, a PE ratio of -79.75 and a beta of 1.12. Roivant Sciences has a 52 week low of $12.90 and a 52 week high of $42.25.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. Equities analysts predict that Roivant Sciences will post -2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mayukh Sukhatme sold 284,707 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at $675,364,288.75. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,055,913 shares of company stock valued at $107,261,258 in the last three months. 8.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in shares of Roivant Sciences by 15.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after acquiring an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after acquiring an additional 34,341 shares during the period. American Century Companies Inc. boosted its position in Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp grew its stake in Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after purchasing an additional 1,181 shares during the period. Institutional investors own 64.76% of the company’s stock.

Key Headlines Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant and its Pulmovant subsidiary reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD), a serious condition with substantial unmet medical needs. The company also disclosed that the Phase 3 PHrontier study is underway, providing a potential path toward a larger value-creating catalyst. Roivant Announces Positive Results from PHocus Study
• Positive Sentiment: Coverage highlighted that mosliciguat met the goals of its mid-stage study, helping drive investor enthusiasm and positioning the drug as a potentially important lung-disease asset. Roivant’s Experimental Lung Disease Drug Meets Goals
• Positive Sentiment: Jefferies raised its price target for ROIV to $52 from $42 and maintained a Buy rating, reflecting increased confidence following the clinical update. Unusually heavy call-option buying also indicates elevated near-term bullish speculation.
• Positive Sentiment: Roivant and Priovant reportedly received FDA approval for Lisraya, described as the first oral treatment for dermatomyositis. The approval gives the partners a differentiated commercial product in a rare disease with limited treatment options. Roivant Wins Approval for the First Oral Dermatomyositis Drug
• Neutral Sentiment: Lisraya launched with a reported list price of $35,000 per 30-day supply, underscoring substantial revenue potential but leaving reimbursement, patient access, and adoption as key commercial risks. What Lisraya’s $35,000 Monthly Price Could Mean for Roivant

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.